Role of wild-type p53-induced phosphatase 1 in cancer (Review)
- Authors:
- Zhi‑Peng Wang
- Ye Tian
- Jun Lin
-
Affiliations: Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China - Published online on: July 27, 2017 https://doi.org/10.3892/ol.2017.6685
- Pages: 3893-3898
This article is mentioned in:
Abstract
 |
|
Jackson SP and Bartek J: The DNA-damage response in human biology and disease. Nature. 461:1071–1078. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Harper JW and Elledge SJ: The DNA damage response: Ten years after. Mol Cell. 28:739–745. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lord CJ and Ashworth A: The DNA damage response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Le Guezennec X and Bulavin DV: WIP1 phosphatase at the crossroads of cancer and aging. Trends Biochem Sci. 35:109–114. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'Connor PM and Appella E: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 94:6048–6053. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, et al: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 31:210–215. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nakagawa H, Wardell CP, Furuta M, Taniguchi H and Fujimoto A: Cancer whole-genome sequencing: Present and future. Oncogene. 34:5943–5950. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M and Donehower LA: The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27:123–135. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lowe J, Cha H, Lee MO, Mazur SJ, Appella E and Fornace AJ Jr: Regulation of the Wip1 phosphatase and its effects on the stress response. Front Biosci (Landmark Ed). 17:1480–1498. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson CW, et al: Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell. 23:757–764. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Nannenga B and Donehower LA: PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19:1162–1174. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A and Minami Y: Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13:1170–1180. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Crescenzi E, Raia Z, Pacifico F, Mellone S, Moscato F, Palumbo G and Leonardi A: Down-regulation of wild-type p53-induced phosphotase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells. J Biol Chem. 288:16212–16224. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Ma O, Nguyen TA, Jones SN, Oren M and Donehower LA: The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 12:342–354. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Lin L, Guo H, Yang J, Jones SN, Jochemsen A and Lu X: Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res. 69:7960–7968. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen TA, Slattery SD, Moon SH, Darlington YF, Lu X and Donehower LA: The oncogenic phosphatase Wip1 negatively regulates nucleotide excision repair. DNA Repair (Amst). 9:813–823. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chew J, Biswas S, Shreeram S, Humaidi M, Wong ET, Dhillion MK, Teo H, Hazra A, Fang CC, López-Collazo E, et al: Wip1 phosphatase is a negative regulator of NF-kappaB signaling. Nat Cell Biol. 11:659–666. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Filipponi D, Muller J, Emelyanov A and Bulavin DV: Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation. Cancer Cell. 24:528–541. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K and Roninson IB: A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59:3761–3767. 1999.PubMed/NCBI | |
|
te Poele RH, Okorokov AL, Jardine L, Cummings J and Joel SP: DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62:1876–1883. 2002.PubMed/NCBI | |
|
Emelyanov A and Bulavin DV: Wip1 phosphatase in breast cancer. Oncogene. 34:4429–4438. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, Tanner M, Tirkkonen M and Isola J: Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res. 63:8861–8868. 2003.PubMed/NCBI | |
|
Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E and Bulavin DV: The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene. 26:2502–2506. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G and Choi J: Overexpression of the Wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat. 101:269–278. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H and Lu X: Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res. 70:7176–7186. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Li D and Kovalchuk O: p53 Ser15 phosphorylation and histone modifications contribute to IR-induced miR-34a transcription in mammary epithelial cells. Cell Cycle. 12:2073–2083. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Spike BT and Wahl GM: P53, stem cells, and reprogramming: Tumor suppression beyond guarding the genome. Genes Cancer. 2:404–419. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kong W, Jiang X and Mercer WE: Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biol Ther. 8:555–563. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pärssinen J, Alarmo EL, Karhu R and Kallioniemi A: PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genet Cytogenet. 182:33–39. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liang CH, Jiao BH, Lu SK, Guo EK and Zhang GY: The expression of proto-oncogene Wip1 in human glioblastoma multiforme and cell lines. Chin J Neuro Oncol. 9:1–6. 2011. | |
|
Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA and Kumar R: Wip1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One. 10:e01156352015. View Article : Google Scholar : PubMed/NCBI | |
|
Buss MC, Remke M, Lee J, Gandhi K, Schniederjan MJ, Kool M, Northcott PA, Pfister SM, Taylor MD and Castellino RC: The Wip1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. Oncogene. 34:1126–1140. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, et al: Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet. 46:726–730. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Barone G, Tweddle A, Shohet JM, Chesler L, Moreno L, Pearson AD and Van Maerken T: MDM2-p53 interaction in paediatric solid tumours: Preclinical rationale, biomarkers and resistance. Curr Drug Targets. 15:114–123. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, et al: Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 488:49–56. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Buss MC, Read TA, Schniederjan MJ, Gandhi K and Castellino RC: HDM2 promotes Wip1-mediated medulloblastoma growth. Neuro Oncol. 14:440–458. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, et al: Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 27:1627–1636. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J and Imoto I: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res. 9:1995–2004. 2003.PubMed/NCBI | |
|
Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, et al: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 15:2269–2280. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ali AY, Abedini MR and Tsang BK: The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene. 31:2175–2186. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ali AY, Kim JY, Pelletier JF, Vanderhyden BC, Bachvarov DR and Tsang BK: Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Mol Carcinog. 54:1301–1314. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ and Tsang BK: Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum. Ann NY Acad Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tan DS and Kaye S: Ovarian clear cell adenocarcinoma: A continuing enigma. J Clin Pathol. 60:355–360. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim SJ, Park WS, et al: MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 33:2557–2567. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis, tumorigenecity, and prognosis of hepatocellular carcinoma. Hepatology. 51:836–845. 2010.PubMed/NCBI | |
|
Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, Zhang H, Chen X, Yang Y and Liu G: miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase 2 (MMP2). PLoS One. 8:e701922013. View Article : Google Scholar : PubMed/NCBI | |
|
Ding DP, Chen ZL, Zhao XH, Wang JW, Sun J, Wang Z, Tan FW, Tan XG, Li BZ, Zhou F, et al: miR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis. 32:1025–1032. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Li D, Sidler C, Rodriguez-Juarez R, Singh N, Heyns M, Ilnytskyy Y, Bronson RT and Kovalchuk O: A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1. Oncotarget. 6:9937–9950. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Oda T, Tsuda H, Scarpa A, Sakamoto M and Hirohashi S: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 52:6358–6364. 1992.PubMed/NCBI | |
|
Li GB, Zhang XL, Yuan L, Jiao QQ, Liu DJ and Liu J: Protein phosphatase magnesium-dependent 1 δ (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma. PLoS One. 8:e607752013. View Article : Google Scholar : PubMed/NCBI | |
|
Koo SH, Kwon KC, Ihm CH, Jeon YM, Park JW and Sul CK: Detection of genetic alterations in bladder tumors by comparative genomic hybridization and cytogenetic analysis. Cancer Genet Cytogenet. 110:87–93. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Zhu H, Zhang H, Zhang L, Ding Q and Jiang H: Targeting PPM1D by lentivirus-mediated RNA interference inhibits the tumorigenicity of bladder cancer cells. Braz J Med Bio Res. 47:1044–1049. 2014. View Article : Google Scholar | |
|
Lin J, Zhang Q, Lu Y, Xue W, Xu Y and Hu X: Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating wip1. PLoS One. 9:e984182014. View Article : Google Scholar : PubMed/NCBI | |
|
Goloudina AR, Mazur SJ, Appella E, Garrido C and Demidov ON: Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xl ratio. Cell Cycle. 11:1883–1887. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV, Mazur SJ, Appella E, Garrido C and Demidov ON: Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci USA. 109:E68–E75. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sun GG, Wang YD, Liu Q and Hu WN: Expression of Wip1 in kidney carcinoma and its correlation with tumor metastasis and clinical significance. Pathol Oncol Res. 21:219–224. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Qi L, Han W, Wan X, Jiang S, Li Y, Xie Y, Liu L, Zeng F, Liu Z and Zu X: Overexpression of Wip1 is associated with biologic behavior in human clear cell renal cell carcinoma. PLoS One. 9:e1102182014. View Article : Google Scholar : PubMed/NCBI | |
|
Sun GG, Zhang J, Ma XB, Wang YD, Cheng YJ and Hu WN: Overexpression of wild-type p53-induced phosphatase1 confers poor prognosis of patients with nasopharyngeal carcinoma. Pathol Oncol Res. 21:283–291. 2015. View Article : Google Scholar : PubMed/NCBI |
